Abstract

You have accessJournal of UrologyCME1 May 2022PD58-04 A COMPREHENSIVE LIQUID BIOPSY TO DETECT PRIMARY UPPER TRACT UROTHELIAL CARCINOMA: A PILOT STUDY Alireza Ghoreifi, Stephanie Shishido, Jeremy Mason, George Courcoubetis, Manju Aron, Inderbir Gill, Monish Aron, Mihir Desai, Siamak Daneshmand, Peter Kuhn, and Hooman Djaladat Alireza GhoreifiAlireza Ghoreifi More articles by this author , Stephanie ShishidoStephanie Shishido More articles by this author , Jeremy MasonJeremy Mason More articles by this author , George CourcoubetisGeorge Courcoubetis More articles by this author , Manju AronManju Aron More articles by this author , Inderbir GillInderbir Gill More articles by this author , Monish AronMonish Aron More articles by this author , Mihir DesaiMihir Desai More articles by this author , Siamak DaneshmandSiamak Daneshmand More articles by this author , Peter KuhnPeter Kuhn More articles by this author , and Hooman DjaladatHooman Djaladat More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002643.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Diagnosis and preoperative risk stratification of patients with upper tract urothelial carcinoma (UTUC) present distinct challenges given the limitations of current available diagnostic tools, such as imaging and endoscopic biopsy. Blood-based liquid biopsy has emerged as a novel diagnostic and prognostic biomarker in cancer patients, yet the possibility of this test in UTUC patients is unknown. The aim of this study is to explore the feasibility of a liquid biopsy to detect UTUC. METHODS: Under an IRB-approved protocol, blood samples were collected from primary UTUC patients before radical nephroureterectomy between May and October 2021. Patients with concomitant bladder cancer or those with positive bladder biopsies within the past 3 months were excluded. The samples were analyzed using third generation of comprehensive high-definition single cell assay (HDSCA3.0) to detect single cell circulatory tumor cells (CTCs). The findings were compared to the blood samples of normal blood donors (NBDs) who had no known pathology. RESULTS: A total of 5 UTUC patients and 5 NBDs were included in the pilot analysis. Demographic and pathological features of the UTUC patients are shown in Table 1. All patients showed papillary UTUC with no variant histology. HDSCA3.0 analysis indicated that rare cells are detectable in the peripheral blood collected from UTUC patients with high heterogeneity (Figure 1-A). The total rare cell count detected in UTUC patient samples was significantly higher than that from the NBDs (p-value = 0.009). Similar trend was seen in total CK+ cells (p=0.009), DAPI|CK (p=0.009), DAPI|Vim (0.028), DAPI|CK|Vim|CD45/CD31 (p=0.009), and DAPI only (p=0.009) (Figure 1-B). CONCLUSIONS: In this pilot study, the proposed liquid biopsy is feasible in UTUC patients. UTUC samples showed significantly higher rare cell count compared to the normal blood donors. A larger sample size study, including follow-up blood samples, to validate the accuracy of this test is the next step. Source of Funding: USC Urology Pilot Research Program © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e1012 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alireza Ghoreifi More articles by this author Stephanie Shishido More articles by this author Jeremy Mason More articles by this author George Courcoubetis More articles by this author Manju Aron More articles by this author Inderbir Gill More articles by this author Monish Aron More articles by this author Mihir Desai More articles by this author Siamak Daneshmand More articles by this author Peter Kuhn More articles by this author Hooman Djaladat More articles by this author Expand All Advertisement PDF DownloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call